



Wientalstraße 13,
3011 Purkersdorf, AUSTRIA

+43 680 144 44 22

dirk@strickmann.org

www.linkedin.com/in/
dirk-strickmann

Dr. Dirk B. Strickmann

Expert for bioanalysis, SM drug development & management

Personal summary

I have over 24 years of experience in drug development as chemist, bioanalyst, and R&D expert covering all phases of small molecule (SM) drug discovery and development. I supported the development of lefamulin (Xenleta®) from initial synthesis through screening processes, the preclinical and clinical development phases to the regulatory submission. I have more than 10 years of experience in management functions e.g. as managing director of Nabriva Therapeutics GmbH. In my last positions, I set up the InnoFly BioCenter (IBC) as managing director and, as director DMPK/ADME, I helped establishing Rockfish Bio's drug development unit. Due to Rockfish Bio's temporary cessation of operations and the successful establishment of IBC, I am now available for a new challenge.

Professional experience and major achievements

Since 05/2020

DBS CONSULTING, Purkersdorf, Austria

Consultant

I offer consulting in the areas of bioanalysis (e.g. bioanalytical CRO management, review of bioanalytical documents), small molecule drug development (planning of ADME/DMPK and DDI studies through all phases of non-clinical and clinical development), scientific writing (INDs, IBs, NDAs, MAAs, etc.), due diligence, research facility organization (e.g. support during planning of new or modernization of old research facilities), and management consulting (e.g. corporate resilience optimization, interim CEO, etc.).

10/2024 – 12/2025

ROCKFISH BIO AG, Vienna, Austria

Director DMPK/ADME

I helped setting up the non-clinical ADME/DMPK program for novel small molecule senolytics. Furthermore, I set up the HSE concept for Rockfish Bio.

09/2023 – 12/2025

INNOFLY BIOCENTER (IBC) GMBH, Vienna, Austria

Managing Director

I built up and managed the IBC site hosting four small biotechnology companies and an accounting company.

02/2006 – 07/2023

NABRIVA THERAPEUTICS GMBH, Vienna, Austria

05/2023 – 07/2023

Freelancer (Freier Dienstnehmer)

I supported the wind-down process of the company.

06/2021 – 05/2023

Managing Director (Handelsrechtlicher Geschäftsführer)

I was responsible for day-to-day business, with a focus on organizational, technical, and facility-related aspects and safety & security issues.

09/2016 – 05/2023

Senior Director DMPK

I was responsible for all internal and external tasks related to bioanalytical aspects and various ADME/DMPK aspects.

01/2015 - 05/2023

Managing Director in terms of Trade Law (Gewerberechtlicher Geschäftsführer)

I was responsible for compliance with Austrian Trade Law and others

08/2012 - 10/2015

Biology Lead of Discovery Unit

I was coordinating all biological activities (bioanalytical, microbiology, and *in vivo* pharmacology laboratory) for Nabriva's discovery unit and was dealing as counterpart to the Chemistry Lead.

09/2011 - 08/2016

Director Bioanalytics

03/2007 - 08/2011

Principal Scientist – Bioanalytics

02/2006 - 03/2007

Principal Scientist – Analytical Chemistry**01/2002 – 01/2006****SANDOZ GMBH - ANTIBIOTIC RESEARCH INSTITUTE**, Vienna, Austria

10/2002 - 01/2006

Head of analytical laboratory

01/2002 - 10/2002

Research Associate**01/2001 - 12/2001****DEPARTMENT OF INORGANIC CHEMISTRY – BIOINORGANIC AND COMPLEX CHEMISTRY**, University of Vienna, Austria**Postdoctoral Fellowship**, Lise-Meitner scholarship of the Austrian Science Fund (FWF)

Recent professional activities and achievements

07/2020

Approval for Xenleta® (Lefamulin) by EMA and Health Canada

08/2019

Approval for Xenleta® (Lefamulin) by U.S. FDA

05/2019

Marketing authorization application (MAA) for Xenleta® (Lefamulin) submitted to the EMA

12/2018

New Drug Application (NDA) for Xenleta® (Lefamulin), submitted to the U.S. FDA (Co-authoring for the eCTD modules 2.4, 2.6.1, 2.6.4, 2.6.5, 2.7.1, 2.7.2, and 2.7.4)

Education

07/2000

Dr. rer. nat. in Pharmaceutical Chemistry (≙ PhD)*Dept. of Pharmaceutical Chemistry, University of Münster, Germany*

10/1996 – 07/2000

Doctoral thesis*Dept. of Pharmaceutical Chemistry, University of Münster, Germany*
Supervisor: Prof. Dr. Gottfried Blaschke

10/1990 – 07/1996

Studies of Chemistry (Diplom-Chemiker ≙ MSc),
University of Münster, Germany

Publications, patents, references

List of publications and patents as well as references, certificates, letters of recommendation, and a more detailed CV are available upon request.

Additional skills

German (mother tongue)
English (fluent)MS WORD,
EXCEL,
ACCESS,
POWERPOINT,
Phoenix™ WinNonlin® v6.3
(Pharsight),
Veeva Vault

- Safety expert for life science laboratories
- Expert for corporate resilience
- Chromatography: LC-MS(/MS), LC-UV, IC, GC-FID
- Spectrometry: MS (Ion trap MS, MS/MS, ESI, APCI)
- Electrophoresis: CE ((a)chiral), CE-MS, CEC, CEC-MS
- Handling and preparation of biological samples
- Quantification of drugs in tissue samples (plasma, blood, urine, feces, organs)
- Validation of analytical methods according to guidelines
- PK parameter calculations with WinNonlin